Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Assenat

Showing results (141-150 of 153) with videos related to

Pageof 16
Sort By:
The Lancet. Oncology|April 8, 2018
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled studyLorenza Rimassa, Eric Assenat, Markus Peck-Radosavljevic, et al.
JAMA Network Open|September 8, 2021
Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal CancerAlain R Thierry, Brice Pastor, Ekaterina Pisareva, et al.
Journal of Hepatology|August 1, 2024
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinomaGeorge Lau, Ghassan K Abou-Alfa, Ann-Lii Cheng, et al.
The Lancet. Gastroenterology & Hepatology|November 9, 2020
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trialEtienne Garin, Lambros Tselikas, Boris Guiu, et al.
Liver Cancer|March 6, 2023
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 TrialZhenggang Ren, Michel Ducreux, Ghassan K Abou-Alfa, et al.
The Lancet. Oncology|December 16, 2021
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trialThomas Yau, Joong-Won Park, Richard S Finn, et al.
The Lancet. Oncology|June 1, 2026
[<sup>177</sup>Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trialEric Baudin, Alice Durand, Amandine Beron, et al.
Hepatology (Baltimore, Md.)|April 8, 2026
Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in patients with BCLC a hepatocellular carcinoma and high risk of recurrence (NIVOLEP trial)Pierre Nahon, Marianne Ziol, Long Pan, et al.
The New England Journal of Medicine|December 22, 2018
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Pascal Hammel, Mohamed Hebbar, et al.
Evolutionary Applications|February 12, 2013
Applying ecological and evolutionary theory to cancer: a long and winding roadFrédéric Thomas, Daniel Fisher, Philippe Fort, et al.
Pageof 16

Showing results (141-150 of 153) with videos related to

Sort By:
Pageof 16
The Lancet. Oncology|April 8, 2018
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled studyLorenza Rimassa, Eric Assenat, Markus Peck-Radosavljevic, et al.
JAMA Network Open|September 8, 2021
Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal CancerAlain R Thierry, Brice Pastor, Ekaterina Pisareva, et al.
Journal of Hepatology|August 1, 2024
Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinomaGeorge Lau, Ghassan K Abou-Alfa, Ann-Lii Cheng, et al.
The Lancet. Gastroenterology & Hepatology|November 9, 2020
Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trialEtienne Garin, Lambros Tselikas, Boris Guiu, et al.
Liver Cancer|March 6, 2023
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 TrialZhenggang Ren, Michel Ducreux, Ghassan K Abou-Alfa, et al.
The Lancet. Oncology|December 16, 2021
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trialThomas Yau, Joong-Won Park, Richard S Finn, et al.
The Lancet. Oncology|June 1, 2026
[<sup>177</sup>Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trialEric Baudin, Alice Durand, Amandine Beron, et al.
Hepatology (Baltimore, Md.)|April 8, 2026
Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in patients with BCLC a hepatocellular carcinoma and high risk of recurrence (NIVOLEP trial)Pierre Nahon, Marianne Ziol, Long Pan, et al.
The New England Journal of Medicine|December 22, 2018
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic CancerThierry Conroy, Pascal Hammel, Mohamed Hebbar, et al.
Evolutionary Applications|February 12, 2013
Applying ecological and evolutionary theory to cancer: a long and winding roadFrédéric Thomas, Daniel Fisher, Philippe Fort, et al.
Pageof 16